![](/img/cover-not-exists.png)
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro
Zhu, Liancheng, Lopez, Salvatore, Bellone, Stefania, Black, Jonathan, Cocco, Emiliano, Zigras, Tiffany, Predolini, Federica, Bonazzoli, Elena, Bussi, Beatrice, Stuhmer, Zachary, Schwab, Carlton L., EnVolume:
36
Language:
english
Journal:
Tumor Biology
DOI:
10.1007/s13277-015-3218-4
Date:
July, 2015
File:
PDF, 863 KB
english, 2015